Rubicon Research IPO Guide: Date, Price, Review & Allotment Updates
The Rubicon Research IPO is one of the most anticipated public offerings in India’s pharmaceutical sector this year. Scheduled to open on October 9, 2025, and close on October 13, 2025, this IPO has garnered significant attention from investors. With a price band set between ₹461 and ₹485 per share, Rubicon Research aims to raise approximately ₹1,377.50 crore through this offering.
About Rubicon Research
Rubicon Research Limited is a Mumbai-based pharmaceutical company specializing in the development and manufacturing of generic formulations. The company has a strong presence in regulated markets, particularly in the United States, focusing on high-value, niche therapeutic areas. With a robust R&D pipeline and a commitment to quality, Rubicon Research has positioned itself as a significant player in the global pharmaceutical industry.
IPO Details
- Issue Type: Book Building Offer
- Price Band: ₹461 – ₹485 per share
- Lot Size: 30 shares
- Issue Size: ₹1,377.50 crore
- Fresh Issue: ₹500 crore
- Offer for Sale: ₹877.50 crore
- Listing: Expected on October 16, 2025, on both BSE and NSE
- Anchor Investor Allocation: Scheduled for October 8, 2025
Subscription & Investor Response
The IPO opens for subscription on October 9, 2025, and closes on October 13, 2025. As of now, the grey market premium (GMP) stands at ₹80, indicating positive investor sentiment. The retail portion is expected to be 10%, with a minimum application size of ₹14,550 for 30 shares. The allotment date is set for October 14, 2025, and the listing is anticipated on October 16, 2025.
IPO Allotment & Listing Updates
- Allotment Finalization: October 14, 2025
- Refund Initiation: October 15, 2025
- Share Credit to Demat Accounts: October 15, 2025
- Listing Date: October 16, 2025
Investors can check their allotment status through the official registrar’s website or via their respective brokers. The listing will provide insights into the market’s reception of Rubicon Research’s debut on the stock exchanges.
Pros & Cons of Investing in Rubicon Research IPO
Pros
- Strong Financials: Consistent revenue growth and profitability.
- Global Presence: Established markets in the U.S. and other regulated regions.
- Robust R&D Pipeline: Focus on high-value, niche therapeutic areas.
- Experienced Management: Leadership with a proven track record in the pharmaceutical industry.
Cons
- Regulatory Risks: Exposure to stringent regulations in international markets.
- Market Competition: Intense competition in the generic pharmaceutical sector.
- Currency Fluctuations: Impact of exchange rate variations on profitability.
Conclusion
The Rubicon Research IPO presents a compelling investment opportunity for those looking to tap into the growing pharmaceutical sector. With its strong financials, global presence, and robust R&D pipeline, the company is well-positioned for future growth. However, potential investors should consider the associated risks, including regulatory challenges and market competition, before making investment decisions.
FAQS:
You can guess the IPO listing price by checking the grey market premium, company financials, past IPO trends, and market demand. Strong demand usually leads to a higher listing price.
IPO allotment is generally fair but depends on demand. Retail investors get a small portion if oversubscribed. Allocation is usually done randomly or proportionally.
Choose an IPO price by comparing the price band, company growth, market conditions, and peer IPOs. Look for reasonable valuations, not just hype, before investing.
Disclaimer:
This content is for informational purposes only and is not financial advice. Always conduct your research.
